Affiliation
Fondation Médecins Sans Frontières, Paris, France. office@paris.msf.orgIssue Date
1999-01-27
Metadata
Show full item recordAbstract
Drugs offer a simple, cost-effective solution to many health problems, provided they are available, affordable, and properly used. However, effective treatment is lacking in poor countries for many diseases, including African trypanosomiasis, Shigella dysentery, leishmaniasis, tuberculosis, and bacterial meningitis. Treatment may be precluded because no effective drug exists, it is too expensive, or it has been withdrawn from the market. Moreover, research and development in tropical diseases have come to a near standstill. This article focuses on the problems of access to quality drugs for the treatment of diseases that predominantly affect the developing world: (1) poor-quality and counterfeit drugs; (2) lack of availability of essential drugs due to fluctuating production or prohibitive cost; (3) need to develop field-based drug research to determine optimum utilization and remotivate research and development for new drugs for the developing world; and (4) potential consequences of recent World Trade Organization agreements on the availability of old and new drugs. These problems are not independent and unrelated but are a result of the fundamental nature of the pharmaceutical market and the way it is regulated.PubMed ID
9929090Additional Links
http://jama.ama-assn.org/cgi/content/full/281/4/361?ijkey=v7ANi6A7kiVu2&keytype=ref&siteid=amajnlsLanguage
enDescription
To access this article, click on "Additional Links"ISSN
0098-7484Collections
Related articles
- Trade, TRIPS, and pharmaceuticals.
- Authors: Smith RD, Correa C, Oh C
- Issue date: 2009 Feb 21
- Spurious and counterfeit drugs: a growing industry in the developing world.
- Authors: Gautam CS, Utreja A, Singal GL
- Issue date: 2009 May
- [Patents and availability of essential drugs].
- Authors: Carné X
- Issue date: 2007 Nov 3
- Can Brazil play a more important role in global tuberculosis drug production? An assessment of current capacity and challenges.
- Authors: Gemal A, Keravec J, Menezes A, Trajman A
- Issue date: 2013 Mar 27
- TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
- Authors: 't Hoen E
- Issue date: 2002 Spring